Introduction {#s1}
============

Since 2000, artemisinin combination therapies (ACTs) have become widely adopted as first-line treatment policy for uncomplicated P. falciparum malaria in many endemic countries in response to parasite resistance that rendered previous first line treatments ineffective \[[@pmed-0050226-b001],[@pmed-0050226-b002]\]. A secondary factor in the policy choice of ACT has been the proven ability of the artemisinin component to reduce patient gametocytaemia and infectiousness more than previous first-line treatments \[[@pmed-0050226-b003]--[@pmed-0050226-b006]\], which shows potential to translate into a reduction in overall transmission intensity as use of ACT is scaled up \[[@pmed-0050226-b007]\]. With the renewed interest in minimising transmission and moving toward malaria elimination \[[@pmed-0050226-b008]\], it is increasingly important to evaluate the ability of antimalarial treatments not only to cure disease, but also to reduce transmission. Understanding how pharmacological properties of ACT and other antimalarials affect transmission, as well as choice of delivery strategies, can help to maximise the impact of available resources.

Evidence for transmission or disease reductions following ACT deployment initially came from studies in South East Asia \[[@pmed-0050226-b009]--[@pmed-0050226-b012]\] and Southern Africa \[[@pmed-0050226-b013]\] which recorded a reduction in population P. falciparum prevalence or disease incidence after ACT became the main treatment for clinical malaria in the area. Since then, data from a number of settings including Zanzibar \[[@pmed-0050226-b014]\] and Rwanda have demonstrated a significant reduction in malaria cases following ACT introduction. While these studies are consistent in suggesting a benefit of ACT, they had observational, time-trend designs without control groups, and it is unclear how much of the effect in these settings was attributable to ACT and how much to other factors including simultaneous introduction of vector control measures \[[@pmed-0050226-b011],[@pmed-0050226-b013]\], changes in climatic conditions \[[@pmed-0050226-b010]\], and change in diagnostic quality control. Furthermore, these observations come from relatively low transmission settings. In higher-transmission settings, the asymptomatic reservoir of infection may limit the potential for transmission reduction by treatment of symptomatic cases, because greater exposure increases immunity and the chance of an infection remaining asymptomatic \[[@pmed-0050226-b015],[@pmed-0050226-b016]\].

A previous mathematical model of symptomatic case management predicted moderate to substantial impact of the nonartemisinin-based antimalarials sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) on age-prevalence patterns of infection and rates of severe disease and mortality under scenarios of 40% or 100% coverage \[[@pmed-0050226-b017]\]. Rates of uncomplicated clinical malaria episodes were reduced in low but not high transmission settings. Understanding to what extent ACTs with their additional gametocytocidal effects can reduce transmission in settings where partially effective treatments are already in place would aid malaria control agencies who currently must choose how to divide resources between drug purchases, drug delivery strategies, and other control interventions. The decision to maximise the coverage of the ACT class of drugs beyond the formal health care sector has substantial cost implications given their higher price \[[@pmed-0050226-b018]\], but it would be supported if ACT were likely to have a substantial effect on transmission. Choosing to invest in improved diagnostic techniques can save on overtreatment of fever cases with ACT; however, the importance of this widespread presumptive treatment for keeping transmission levels down needs to be investigated.

With increasing investment in research, the range of drugs in development for treatment of malaria is widening and a greater number are also becoming available in combination with artemisinins as ACT \[[@pmed-0050226-b019]\]. The stronger gametocytocidal activity of artemisinin derivatives compared to previous first-line antimalarials \[[@pmed-0050226-b020]\] has received the most attention in relation to potential transmission reductions by treatment \[[@pmed-0050226-b007]\]. However, two other main drug properties impact on transmission: prophylaxis and efficacy at clearing parasitaemia. Artemisinin derivatives have a very short prophylactic time in relation to other antimalarials, and although they remain highly efficacious in most areas of the world due to lack of parasite resistance, there are nonartemisinin antimalarial regimens that are of comparable efficacy in some regions \[[@pmed-0050226-b021]\]. Knowledge of the relative importance of these different drug properties in reducing transmission could help guide policy makers in choosing between ACTs with different partner drugs, and in the longer term a replacement first-line treatment, in the eventuality of parasite resistance or prohibitive cost of ACTs.

Here we develop a mathematical model to describe the impact of ACTs and other antimalarials on P. falciparum malaria transmission intensity. We use data from a survey prior to ACT introduction covering six different transmission settings in Tanzania typical of malaria-endemic Africa, in order to characterise rates of infection, symptomatic episodes, and antimalarial use. We then estimate potential transmission reduction following introduction of ACT as a first-line treatment and examine how the size of the reduction depends on coverage, use of diagnostic testing, and how it compares to the impact of alternative drugs with different pharmacodynamics. In this way we aim to elucidate potential goals for ACT policy implementation and inform future choices of first-line treatment.

Methods {#s2}
=======

Data {#s2a}
----

We use data from a cross-sectional malariometric survey of 5,667 residents of Tanzania undertaken during the rainy season (March--June) of 2002 prior to the introduction of ACT in treatment policy or their licensure and wider availability in the private market. Details of the methodology and results of this survey are described in detail elsewhere \[[@pmed-0050226-b022]\]. For our analysis, villages were grouped by region (Kilimanjaro or Tanga) and altitude (\<600 m, 600-1200 m, \>1200 m) which is a good proxy for transmission intensity with an estimated entomological inoculation rate ranging from less than one infectious bite per person per year at high altitudes, to about 100 infectious bites per person per year at low altitudes \[[@pmed-0050226-b023]\]. The data were stratified by age groups of 0--4 y, 5--14 y, and 15--45 y. Symptomatic malaria was defined by fever (37.5°C or above) and parasite density over age- and altitude-specific thresholds calculated previously using the same data \[[@pmed-0050226-b024]\] (age \<5 y, altitude \<600 m: 4,000 parasites/μl; age \<5 y, altitude \>600 m: 1,000 parasites/μl; age 5--15 y, altitude \<600 m: 500 parasites/μl; age 5--15 y, altitude \>600 m: 250 parasites/μl; age 15--45 y, all altitudes: 500 parasites/μl). A summary of these data is presented in [Table 1](#pmed-0050226-t001){ref-type="table"} and in Table II in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}. Use of antimalarials in the last 14 d was self-reported. In two areas of the cross-sectional survey (North and South Pare), parasite resistance testing to the then first-line antimalarial SP was carried out \[[@pmed-0050226-b025]\]. We assumed that triple and double mutations in the *P. falciparum dhfr* and *dhfs* genes, respectively, would cause parasitological failure, i.e., parasites would not be fully cleared by SP treatment and the infection would persist, while the double-mutant *dhfr* would be sufficient to reduce the effective prophylactic time of SP \[[@pmed-0050226-b026]\]. We also assumed that similar resistance levels were present in all regions in the survey to all widely used nonartemisinin antimalarials at the time ([Table 2](#pmed-0050226-t002){ref-type="table"}).

###### 

Summary of Data from Pre-ACT Cross-Sectional Surveys in Six Transmission Settings in Tanzania
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###### 

Key Parameters in the Model with Sources

![](pmed.0050226.t002)

Incidence rates of symptomatic malaria were calculated from the observed prevalence of symptomatic cases by region, altitude and age as prevalence/duration, using estimates of duration of symptoms from the literature ([Table 2](#pmed-0050226-t002){ref-type="table"}). Parasitaemia is assumed to remain asymptomatically once symptoms have ceased (see model below). We calculated age-specific treatment rates per person-year as the proportion reporting use of antimalarials / reporting time window (14 d) × 365. The relative infectiousness of different age groups was based on gametocyte densities (Tables I and II in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}).

Mathematical Model {#s2b}
------------------

Malaria transmission is modelled in human and mosquito populations using a deterministic compartmental structure ([Figure 1](#pmed-0050226-g001){ref-type="fig"}; [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). Humans are age-stratified and can be in one of five states: susceptible, *S*; latent, *E*; infectious and untreated, *I*; infectious and treated, *T*; or protected, *P*, where the latter state is included to model prophylaxis from treatment. Susceptible individuals become infected at a rate dependent on the density of mosquitoes, the human biting rate, the prevalence of infection in the mosquito, and the probability of developing blood stage infection following an infectious bite. The latent period is divided into two stages; during the first the parasites are liver- and early blood-stage and are subpatent (i.e., not detectable on a blood slide), and during the second stage the infection becomes patent. The infection then develops to the infectious, untreated state *I*, which is divided into four stages with infectiousness greatest in the first two stages and lower in subsequent stages to replicate patterns observed in longitudinal human-to-mosquito transmission experiments (Table I in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}) \[[@pmed-0050226-b027]\]. We assume that untreated infections are patent during the first three stages only \[[@pmed-0050226-b028]\]. Treated infections are described below. From the fourth stage of the infectious period, individuals recover to the susceptible state *S*. Superinfections (infection by a new parasite clone in addition to the original infection) occur independently of the initial infection at the same rate as in susceptible, uninfected individuals and upon superinfection individuals return to the first stage of the infectious period, extending the overall duration of parasitaemia. A proportion of infections and superinfections are symptomatic and we assume that symptoms occur at the beginning of an infection and are followed by a longer period of asymptomatic parasitaemia ([Table 2](#pmed-0050226-t002){ref-type="table"}) \[[@pmed-0050226-b029],[@pmed-0050226-b030]\]. The model is stratified into three age groups (0--4 y, 5--14 y, and 15+ y) to correspond with the data. Malaria-attributable deaths are not explicitly incorporated. We allow for heterogeneity of exposure by additionally stratifying into two risk groups such that 10% of individuals receive 80% of bites from mosquitoes \[[@pmed-0050226-b031]\]. Immunity is modelled by incorporating age-dependency in the probability that an infectious bite develops into a blood stage infection \[[@pmed-0050226-b032]\], the proportion of infections which become symptomatic \[[@pmed-0050226-b033],[@pmed-0050226-b034]\], the rate that an infection progresses to the final subpatent stage (but not the overall duration of infection \[[@pmed-0050226-b035]\]), and infectiousness to mosquitoes \[[@pmed-0050226-b036],[@pmed-0050226-b037]\]. We assume negligible short-term change in immunity so that these parameters do not vary over time \[[@pmed-0050226-b038]\]. We also allow for an increase in exposure to mosquito bites with age due to increasing body surface area \[[@pmed-0050226-b032]\]. Susceptible vectors become infected at a rate dependent on the biting rate and the infectiousness of humans. They progress through latent and infectious stages but do not clear infection and die at a constant rate.

![Overview of Model Structure\
The main states and transitions of the transmission cycle and treatment in the human population are shown, including presumptive treatment (dashed lines). Here one age and exposure group and a single type of antimalarial treatment are represented.](pmed.0050226.g001){#pmed-0050226-g001}

Nonartemisinin treatment with a given rate of parasitological failure representing widely used antimalarials at the time of the Tanzania survey \[[@pmed-0050226-b025]\] is introduced after the model has reached endemic equilibrium in the absence of treatment ([Figure 2](#pmed-0050226-g002){ref-type="fig"}). After reaching a second equilibrium in the presence of the nonartemisinin treatment, which represents transmission at the time of the survey in a given area, a proportion of the failing nonartemisinin treatments are replaced by ACT or another efficacious antimalarial and the model is allowed to reach a third equilibrium. A constant proportion of symptomatic individuals are treated. Treatment can reduce transmission in three ways in the model: by reducing the duration for which treated individuals are infectious (length of time gametocytes remain in the bloodstream), reducing their infectiousness (density and infectivity of gametocytes), and providing prophylaxis. The efficacy of an antimalarial also determines its impact on transmission. In our model, the infectious period of those in the treated state *T* is divided into four stages as in untreated individuals. The duration of the infectious period is shorter and the infection is assumed to become subpatent after the first stage. In the case of gametocytocidal antimalarials, infectiousness is reduced by a constant proportion throughout the infectious period relative to untreated individuals. The total duration of effective prophylaxis is equal to the duration of minimum inhibitory antimalarial concentrations in the blood minus the duration of liver stage infection, since current, widely used antimalarials protect only against blood stage parasites. We assume 100% protection from infection during this time. This includes protection from superinfection during the infectious period, and if prophylactic effects persist after parasites are cleared (depending on the antimalarial being used), individuals enter the protected state *P* before returning to the susceptible state *S*. Treatment clears infection with a certain percentage efficacy determined by the prevalence of infections consisting of parasites susceptible to the drug. Treated patients with resistant parasites experience parasitological treatment failure and enter the first stage of the untreated state *I*. Clinical failure, i.e. parasitological failure accompanied by symptoms, is not explicitly incorporated in the model. In our data from the Tanzania survey, individuals were asked if they had used antimalarials within the previous 14 d. Clinical failure usually occurs on average around 5 d after treatment \[[@pmed-0050226-b039]\], so we assume that re-treatment would occur relatively quickly after the first treatment episode. Therefore it would have little effect on the period prevalence measure of antimalarial use within the last 14 d, or the stage at which infection is treated. However, prevalence of symptomatic malaria was measured on the day of the survey only, so we use a relatively high estimate of duration of symptoms ([Table 2](#pmed-0050226-t002){ref-type="table"}) to allow for clinical failure. Individuals in any state can be presumptively treated for malaria regardless of parasitaemia, which provides a period of prophylaxis (see also Model Parameterisation and Validation, below). Infected individuals receiving presumptive treatment also move to the treated state. Full details of the model, parameter values, and justification of the model assumptions are given in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}.

![Example Model Run over Time for One Age and Exposure Group in One Survey Setting\
Initially this shows introduction of infection and baseline endemic equilibrium in the absence of treatment. Nonartemisinins with treatment failure are introduced first and the model is allowed to reach a second equilibrium, matching the prevalence of slide-positive malaria, clinical malaria and self-reported treatment in the Tanzania survey data. ACT or another antimalarial regimen are then introduced, and our main outcomes of interest are the reductions in prevalence and rate of clinical episodes between the second and third equilibriums.](pmed.0050226.g002){#pmed-0050226-g002}

Model Parameterisation and Validation {#s2c}
-------------------------------------

The effects of nonartemisinin and ACT antimalarials on the infectiousness of patients to mosquitoes were estimated from antimalarial trial data, which measured human-to-mosquito transmission, taking into account subpatent gametocytaemia \[[@pmed-0050226-b003],[@pmed-0050226-b040]\]. These data were also used to estimate the duration of infectiousness under different treatment regimens \[unpublished analysis\]. Patients were included in the trial regardless of pretreatment gametocytaemia, and therefore these estimates allow for lack of ACT effect on mature gametocytes \[[@pmed-0050226-b020]\]. Other parameter estimates were obtained from the literature. Key parameter values are given in [Table 2](#pmed-0050226-t002){ref-type="table"} and a full list is provided in Table I in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}.

Following introduction of failing nonartemisinin treatment into the model, the product of the mosquito density and age-specific probability of mosquito-to-human transmission for each age group was varied so that at the subsequent second equilibrium the age prevalence of patent infection fitted the observed values for a given area in the survey data. The proportion of infections that developed symptoms was set for each age group so as to reproduce the observed symptomatic malaria age prevalence for a given area at the second equilibrium. These parameters, used in fitting prevalence in the model output at the second equilibrium, are known to have a wide range of possible values across different settings and age groups (Table I in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}) \[[@pmed-0050226-b032],[@pmed-0050226-b041]\], therefore it was not necessary to set boundary values, and the model output matched the data exactly.

In the survey, an individual\'s infection status at the time of their reported treatment is unknown. Since presumptive treatment without testing for parasitaemia is common in the study area as in most malaria-endemic settings, it is likely that the reported treatment rate exceeds the rate of treatment of symptomatic malaria infections. We assumed that a maximum of 80% of incident symptomatic infections in each age group receive treatment (if the reported age-specific treatment rate in the population is sufficiently large; otherwise, this is calculated to match the prevalence of treatment history in the population). We assumed conservatively that any remaining treatment episodes were presumptive and were equally distributed within each age group regardless of infection state. The rate of presumptive treatment was calculated as the total age-specific rate of treatment per person-year in the population estimated directly from the data minus the age-specific rate of treatment of symptomatic cases (80% of the rate of symptomatic episodes per person-year estimated from prevalence of symptomatic malaria). We assumed that after introducing a new antimalarial there was negligible short-term change in presumptive treatment rates, but the rate of symptomatic malaria was allowed to change after introduction of a new treatment. We also explored the impact of introducing diagnostic testing (microscopy or antibody-based rapid diagnostic tests) together with ACT by removing presumptive treatment of those without a patent infection.

Results {#s3}
=======

ACT Impact on Transmission {#s3a}
--------------------------

The rates of infection, clinical episodes, and treatment in each transmission setting estimated from the survey prior to ACT introduction are shown in [Table 3](#pmed-0050226-t003){ref-type="table"}. The model-estimated impact of delivering ACT at complete coverage is shown in [Figure 3](#pmed-0050226-g003){ref-type="fig"}A and [Table 4](#pmed-0050226-t004){ref-type="table"}. Replacing 100% of current antimalarial treatments with ACT without any change to the rates of antimalarial use in the study area is predicted to decrease the incidence of clinical episodes by between 21.1% and 52.5% and the prevalence of slide-positive infection by 11.5%--52.9%. This relative impact was largest in the setting with the lowest transmission levels pre-ACT (slide-prevalence = 3.7%), and there was a clear trend for decreasing impact as the pre-ACT transmission level became higher. This trend matched the ratio of the antimalarial treatment rate per person-year to the malaria infection rate per person-year in the populations, which also tended to decrease as pre-ACT transmission became higher ([Figure 3](#pmed-0050226-g003){ref-type="fig"}A; [Table 3](#pmed-0050226-t003){ref-type="table"}). However, the absolute impact in terms of the numbers of clinical episodes averted was predicted to be highest in high transmission settings. An estimated 54.1 and 81.5 clinical episodes were prevented per 100 persons per year in the two areas of highest pre-ACT slide-prevalence compared to 4.9 clinical episodes per 100 persons per year in Kilimanjaro\'s lowest-prevalence area. In our analysis, reductions in clinical disease incidence are closely correlated with reductions in infection incidence, because short-term change in population immunity is assumed to be negligible, and therefore clinical disease is an indicator of transmission levels.

###### 

Estimates of Transmission, Disease, and Treatment Rates in Six Transmission Settings in Tanzania Prior to ACT from Survey Prevalence Data and the Model

![](pmed.0050226.t003)

![Model Predictions of ACT Impact on Transmission in Six Transmission Settings in Tanzania Compared to the Pre-ACT Scenario with Failing Nonartemisinin Treatment\
(A) Relative and absolute reductions in clinical episodes achieved by ACT if treatment rates remained the same and there was a 100% switch to ACT. Also shown is the pre-ACT ratio of treatment to infection rate.\
(B) Relative reductions in clinical episodes by ACT coverage.](pmed.0050226.g003){#pmed-0050226-g003}

###### 

Model-Estimated Impact of Different First-Line Treatments on Transmission Outcomes in Six Transmission Settings in Tanzania

![](pmed.0050226.t004)

The time taken to achieve the reduction in infection incidence becomes longer as pre-ACT transmission intensity decreases ([Table 4](#pmed-0050226-t004){ref-type="table"}). With an instantaneous 100% coverage of ACT, 50% of the total reduction achieved is predicted to occur within 1--3 wk in the high-transmission settings, whilst it is predicted to take 2--3 mo in the lowest-transmission settings. The rate at which incidence decreases slows with time ([Figure 2](#pmed-0050226-g002){ref-type="fig"}). Under scenarios of lower coverage of ACT where a proportion of individuals seeking treatment continued to be given the less effective, failing antimalarials used prior to ACT introduction, transmission reductions are predicted to decrease linearly with ACT coverage ([Figure 3](#pmed-0050226-g003){ref-type="fig"}B). A full sensitivity analysis of our results is given in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}.

Influence of Improved Diagnosis {#s3b}
-------------------------------

The importance of presumptive treatment to overall ACT impact was explored by modelling a scenario in which additional testing for the presence of parasites is incorporated into an ACT treatment programme. Under such a programme, individuals without detectable infection who seek treatment are no longer prescribed antimalarials; however, those with asymptomatic infection who have patent parasitaemia (for example, those who seek treatment due to symptoms from another illness) continue to be treated. In the two lowest-transmission settings in Tanzania, reported rates of treatment per person-year in the cross-sectional survey were higher than the estimated rates of clinical episodes ([Table 3](#pmed-0050226-t003){ref-type="table"}), suggesting greater overuse of antimalarials in these areas. Reducing treatment rates through introducing diagnosis reduced ACT impact to some extent in the two lowest transmission settings only ([Figure 4](#pmed-0050226-g004){ref-type="fig"}A). In these settings, the model estimates that a relatively high proportion of antimalarial treatments are used by individuals without symptomatic malaria or detectable infection. This use of treatment reduces transmission less efficiently because it does not target the most infectious individuals, but has a small effect through cure of subpatent infections and prophylaxis. Similarly, the number of treatment courses required to indirectly prevent one clinical episode via transmission impact was greatly reduced by laboratory diagnosis in the two lowest-transmission settings only ([Figure 4](#pmed-0050226-g004){ref-type="fig"}B). Improved diagnosis can reduce treatment rates and thus ACT impact further if we assume a lower proportion of treatment is used by symptomatic cases (Figure VIII in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}).

![Model-Estimated Impact of Introducing Improved Diagnostic Procedures\
Improved diagnostic methods are introduced prior to antimalarial prescription together with a 100% switch to ACT in six transmission settings in Tanzania, compared to no change in current treatment use, (A) on the percentage of clinical episodes prevented and (B) on the efficiency of treatment at reducing transmission.](pmed.0050226.g004){#pmed-0050226-g004}

![Model-Estimated Impact of Introducing Antimalarials with 100% Efficacy and Different Pharmacodynamic Properties\
Impact is shown on (A) clinical episodes and (B) slide-prevalence of infection in six transmission settings in Tanzania, compared to the pre-ACT scenario with failing nonartemisinin treatment assuming a 100% switch to these treatments. Short-acting nongametocytocidal: prophylactic time = 10 d, no specific gametocytocidal action. Short-acting ACT (as [Figure 3](#pmed-0050226-g003){ref-type="fig"}A): prophylactic time = 10 d, with the gametocytocidal action of artemisinin. Long-acting nongametocytocidal: prophylactic time = 25 d, no specific gametocytocidal action. Long-acting ACT: prophylactic time = 25 d, with the gametocytocidal action of artemisinin.](pmed.0050226.g005){#pmed-0050226-g005}

Impact on Transmission of Antimalarials with Different Pharmacodynamic Properties {#s3c}
---------------------------------------------------------------------------------

In addition to investigating ACT impact on transmission, and thus the impact of a gametocytocidal drug, we used the model to examine the importance of the efficacy and prophylactic effects of antimalarials in reducing transmission ([Figure 5](#pmed-0050226-g005){ref-type="fig"}). We consider the impact of individual antimalarials in order to separate out the effects of these drug properties, however this is intended to be purely theoretical since use of any antimalarial alone increases the chance of development of resistance \[[@pmed-0050226-b042]\]. Using data on SP, it is assumed that the nonartemisinin treatments in use in the study area at the time of the survey had only 50% efficacy and a prophylactic time of 7 d due to high levels of resistance mutations \[[@pmed-0050226-b025],[@pmed-0050226-b026]\]. Our results suggest that these treatments were having little impact on transmission with an estimated 0.6%--10.7% lower rate of clinical episodes compared to a scenario without any antimalarials ([Table 4](#pmed-0050226-t004){ref-type="table"}). As before, the impact was largest in the lower-transmission settings.

Replacing 100% of the failing treatments with a theoretical, 100% efficacious nongametocytocidal antimalarial with a prophylactic time of 10 d (as assumed for a short-acting ACT) is estimated to reduce the rate of clinical episodes by 2.5%--12.6% ([Figure 5](#pmed-0050226-g005){ref-type="fig"}A). Again this impact increased as pre-ACT transmission decreased. However, using a nongametocytocidal antimalarial that had a longer prophylactic time of 25 d as well as 100% efficacy substantially increased its impact on transmission ([Figure 5](#pmed-0050226-g005){ref-type="fig"}). Clinical episodes were reduced by 24.0%--33.7% and, in contrast to the gametocytocidal drugs, this impact increased as baseline transmission increased. This relationship was observed despite the lower ratio of treatment rate to infection rate at higher transmission (see [Figure 3](#pmed-0050226-g003){ref-type="fig"}A). In the setting with highest initial slide-prevalence (57.1%), the impact of such a drug on clinical episodes was 60% higher than the predicted impact of a drug with the gametocytocidal effects of ACT and a prophylactic time of 10 d (such as artemether-lumefantrine \[AL\], the most commonly used ACT) ([Figure 5](#pmed-0050226-g005){ref-type="fig"}A; [Table 4](#pmed-0050226-t004){ref-type="table"}). An ACT with a long-acting partner drug (25 d prophylaxis) had the highest impact of all drug types, reducing rates of clinical episodes by 54.1%--69.1%, with the impact tending to increase with pre-ACT transmission levels ([Figure 5](#pmed-0050226-g005){ref-type="fig"}A).

Gametocytocidal drug action was less effective in reducing transmission from an initially high than from a low level because following clearance of gametocytes individuals were more quickly reinfected. By contrast, prophylactic effects were more important for reducing new inoculations and clinical episodes in high- than in low-transmission settings, because there was a greater chance of receiving an infectious challenge during the prophylactic period. Prophylactic and, to some extent, gametocytocidal drugs are predicted to have less effect on infection prevalence than on the incidence of clinical episodes in higher-transmission settings ([Figure 5](#pmed-0050226-g005){ref-type="fig"}B). A similar pattern is observed with other malaria control interventions \[[@pmed-0050226-b043]\] because of the nonlinear relationship between prevalence and incidence of malaria infection \[[@pmed-0050226-b044]\]. This relationship arises because the time period between new parasite inoculations is shorter at higher transmission and superinfection is more common. Therefore, preventing an inoculation does not reduce the amount of person-time spent infected, and therefore prevalence, as much as it would in a lower-transmission setting.

Sensitivity Analysis {#s3d}
--------------------

Model results were relatively robust to variations in the majority of key parameters (full details provided in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}), but we found that ACT impact size would be lower in populations with high heterogeneity in exposure (Figure V in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). The size of ACT gametocytocidal effects in treated individuals as well as prophylactic effects was an important determinant of transmission reductions (Figure VI in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). We also confirmed that the trends shown in the results still existed in a much simplified version of the model, which did not use the survey data and ignored presumptive treatment, treatment failure, age, and immune effects, assuming a constant proportion of infections treated in all areas. Gametocytocidal drugs still had most impact in lower-transmission settings, and the reverse was true for prophylactic drug effects (Figure IV in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Our model shows the potential for an appreciable impact of ACT on malaria transmission at current rates of antimalarial treatment in our study area of Tanzania. The predicted reductions in prevalence of slide-positive infection at 100% coverage are between 11.5% and 52.9%, which compare with 13%--42% achieved by insecticide-treated bed nets (ITNs) in trial settings \[[@pmed-0050226-b043]\] and, as such, ACT could form an important part of a transmission reduction programme. The estimated reductions in rates of clinical episodes of 21.1%--52.5% with a short-acting ACT are lower than pooled estimates of ITN impact of 50%--62% \[[@pmed-0050226-b043]\]. In higher-transmission settings (\>20% baseline slide-prevalence), ACT is predicted to have its smallest relative impact on transmission as found in a previous model looking at SP-AQ \[[@pmed-0050226-b017]\], due to a combination of a lower proportion of infections being treated and the different dynamics of infection prevalence ([Figure 3](#pmed-0050226-g003){ref-type="fig"}A; Figure IV in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). However, in terms of public health impact, the absolute number of clinical episodes prevented by introducing ACT in high-transmission settings was much greater, and the courses of treatment required per episode indirectly averted was substantially lower given current treatment rates across settings. Furthermore, the direct benefits of effective clearance of parasites for infected individuals would be considerable. More widespread use of diagnostic tools prior to treatment is predicted to increase the efficiency of ACT in reducing transmission per treatment course, especially in lower-transmission settings, although it could result in some reduction in the total impact, as previously suggested \[[@pmed-0050226-b045]\]. Depending on how quickly ACTs are made widely available, significant impact could be seen within a few weeks in higher-transmission settings but would occur over several months in lower-transmission settings. Our analysis deliberately represents an ideal scenario in order to estimate the maximum potential for ACT impact, whilst in reality the difficulties of imperfect patient adherence and of achieving good coverage in all health sectors \[[@pmed-0050226-b001],[@pmed-0050226-b046]\] would reduce the speed and magnitude of transmission reductions, potentially substantially, as seen with ITNs outside trial settings.

Our analysis finds that gametocytocidal properties of antimalarials have the most relative impact in lower-transmission settings, while prophylactic effects have more impact in areas with high transmission. An ACT with the gametocytocidal effects of the artemisinin derivative and the prophylactic effect of a longer-acting partner drug is predicted to have the greatest impact on transmission across all areas in the short-term time scale of our model. ACT with long-acting partner drugs are currently in use in some areas; for example, artesunate-mefloquine is recommended by WHO. The more recently formulated dihydroartemisinin-piperaquine is also likely to become used more widely \[[@pmed-0050226-b047]\]. If used widely in the longer term in higher-transmission settings, the advantage of the prophylactic effects of these long-acting ACTs would need to be weighed against a higher selective pressure for resistant parasite strains \[[@pmed-0050226-b026],[@pmed-0050226-b048],[@pmed-0050226-b049]\]. Careful resistance surveillance would be important. Our finding that a long-acting nongametocytocidal drug regimen could have as much or more effect on transmission than a short-acting ACT in higher-transmission areas similarly needs to be considered bearing resistance development in mind. Such a drug regimen would need to contain two or more efficacious antimalarials in combination. Existing nonartemisinin combinations include SP-AQ and SP-chloroquine, but their use is limited due to widespread resistance \[[@pmed-0050226-b047]\]. However, the predicted impact of long-acting treatments has implications for future development of nonartemisinin combinations and their use as a first-line treatment, particularly if cost or development of artemisinin resistance make ACT a less attractive option. Developing and deploying drugs with stronger gametocytocidal activity than artemisinins would also be highly beneficial for transmission reductions according to our results (Figure VI in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). Primaquine may be one such existing drug, but limited evidence does not show a consistent advantage over artemisinin derivatives \[[@pmed-0050226-b050],[@pmed-0050226-b051]\].

Estimated treatment impact did not vary evenly with baseline slide-prevalence of infection, particularly in the medium-transmission settings ([Figures 3](#pmed-0050226-g003){ref-type="fig"}A, [4](#pmed-0050226-g004){ref-type="fig"}A, and [5](#pmed-0050226-g005){ref-type="fig"}). This is likely to be due partly to sampling variation resulting from the smaller sample size in the area with 18.1% baseline prevalence ([Table 1](#pmed-0050226-t001){ref-type="table"}). The prevalence of symptomatic malaria and reported use of antimalarials are high in this area relative to the others given its measured infection prevalence, resulting in higher estimates of treatment impact. However, as has been found in other endemic populations \[[@pmed-0050226-b052]\], reported use of antimalarials also did not decline evenly with baseline prevalence in the other areas despite larger sample sizes. Variation in ACT impact due to treatment-seeking behaviour of populations is likely to be a real feature of ACT scale-up. Our results should be seen in terms of short-term impact only, since we do not take into account changes in the immunity of populations over time. The necessary data for our model, such as the incidence of infection and the proportion of infections developing symptoms, are rarely measured directly due to the difficulties of detecting all superinfections; therefore, we relied on model estimates from prevalence data, which gave results that were mostly within the range of the few data available \[[@pmed-0050226-b033],[@pmed-0050226-b034]\]. Varying parameters and the model assumptions that affected these estimates caused limited change in the results except in the case of heterogeneity of exposure (see the sensitivity analysis in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). In the highest-transmission setting the estimated incidence of infection and clinical episodes in the pre-ACT setting appear high ([Table 3](#pmed-0050226-t003){ref-type="table"}), but may be reasonable given measured entomological inoculation rates \[[@pmed-0050226-b023]\], and that the survey was conducted during the season of highest transmission and thus true annual rates would be lower. Whilst the prevalence of symptomatic malaria in the survey data decreased with transmission setting, our estimated proportion of infections developing symptoms did not show a clear trend of increasing as would be expected due to decreasing immunity ([Table 3](#pmed-0050226-t003){ref-type="table"}). This trend was visible across the four higher-transmission settings, but not in the two sites with lowest transmission intensity, probably due to the small numbers of cases meeting our definition of symptomatic malaria in these areas ([Table 1](#pmed-0050226-t001){ref-type="table"} in the main text and Table II in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). However, we had estimates of treatment intake in the population, and our results are relatively robust to whether this treatment occurs in symptomatic or asymptomatic individuals (Figure VIIa--b in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). They are more sensitive to the accuracy of our treatment data, which is self-reported, and thus potentially underestimated \[[@pmed-0050226-b053]\]. Our data are limited to individuals under 45 y of age, which in these settings represents around 87% of the population \[[@pmed-0050226-b054]\]. By assuming in our model that individuals over 45 y have the same infection and immunity status as 15- to 45-y-olds, we may underestimate overall immunity levels in this age group to some extent. However, our sensitivity analysis showed that results were not affected substantially by ignoring age structure (Figure VIIi--j in [Text S1](#pmed-0050226-sd001){ref-type="supplementary-material"}). In generalizing our results to other settings it should be borne in mind that our slide-prevalence data represent the peak in annual transmission in these areas, whilst immunity levels in the study populations reflect lower transmission during other times of the year.

Our model predictions are roughly compatible with some of the trends from observational studies in areas where ACT was introduced, although it is uncertain to what extent these trends were attributable to ACT. In studies where transmission was similar to our lowest transmission setting (Kilimanjaro, \>1,200 m) or lower, around 50% \[[@pmed-0050226-b010],[@pmed-0050226-b012]\] to 75% \[[@pmed-0050226-b013]\] reductions in clinical episodes or prevalence occurred following ACT introduction, although there were also changes in vector levels during the same time period. In an area of Zanzibar with transmission levels similar to those of our second-lowest transmission setting (Kilimanjaro 600--1,200 m), little clear change in clinical incidence was seen during 2004 after the introduction of ACT, during which time 34,724 doses of artemether-lumefantrine were dispensed to a population of ∼85,000 \[[@pmed-0050226-b014]\]. We cannot be sure what coverage of ACT this achieved (i.e. what proportion of all antimalarials used by the population were ACT), but in our equivalent setting this would amount to ∼30% coverage and a potential ∼16% reduction in clinical episodes ([Figure 3](#pmed-0050226-g003){ref-type="fig"}B), which could have been masked by the seasonal trends in Zanzibar or diminished by imperfect patient adherence. As well as comparing our results to studies of ACT impact, it is interesting to compare with previous introduction of long-acting nonartemisinins, which received less attention in terms of transmission reductions. For example our model suggests that when SP was first widely introduced as an efficacious drug to replace failing chloroquine treatment, there could have been a 20%--30% reduction in clinical episodes in higher-transmission areas ([Table 4](#pmed-0050226-t004){ref-type="table"}) due to its long prophylactic time. Documented decreases of \>40% in clinical episodes or hospital admissions have coincided with SP introduction in areas of intense transmission in southern Tanzania \[[@pmed-0050226-b055]\] and on the coast of Kenya \[[@pmed-0050226-b045],[@pmed-0050226-b056]\], although as with ACT these studies were observational and took place in the context of increasing vector control. Cluster-randomized trials measuring the transmission impact of different antimalarials used as first line treatment would be valuable in order to confirm observational evidence and the findings of our model.

With the current interest in reducing malaria transmission with a view to elimination of the parasite \[[@pmed-0050226-b057]\], our results suggest that ACT can be a valuable tool as part of a larger programme of control interventions, particularly in lower-transmission settings. We demonstrate that the choice of appropriate ACT partner drugs or alternative first-line treatments for a given transmission setting could play an important role in transmission control. Antimalarial properties therefore need to be taken into account in future drug development and at a national and international level in determining treatment policies if substantial reductions are to be achieved in transmission and morbidity from malaria across endemic countries.
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ACT

:   artemisinin combination therapy

AL

:   artemether-lumefantrine

AQ

:   amodiaquine

AS

:   artesunate

ITN

:   insecticide-treated net

Pf

:   Plasmodium falciparum

SP

:   sulfadoxine-pyrimethamine
